WHAT IS CLAIMED IS:

1. An aqueous etanercept formulation stabilized with sodium chloride, said formulation comprising 25 to 75 mg/ml of etanercept, 75 mM to 150 mM sodium chloride; 1 to 30 mM sodium phosphate, 3% sucrose, wherein the formulation is free of arginine, and where the formulation elicits long term stability.

2. The formulation of claim 1 wherein the formulation elicits long term storage stability as characterized by at least one of:

   SEC analysis at M_3 or T_2 or T_4 of: monomer content greater than 90%; aggregates content of less than 3 wt%; and fragment 3 content less than 5 wt%: and

   HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

3. The formulation of claim 1, wherein the composition has a pH of 6.0 to 6.6; and wherein the composition is characterized by SEC analysis at M_3 or T_2 or T_4 in which: monomer content is greater than 80 wt.%; aggregate(s) content is less than 3 wt.%, and fragment 3 content is less than 8 wt.%.

4. The formulation of claim 1 comprising: 50 mg/ml of etanercept; 75 mM sodium chloride; 10 to 30 mM sodium phosphate; and about 3 wt.% sucrose.

5. The formulation of claim 1 comprising: 50 mg/ml of etanercept; 75mM sodium chloride; 10 to 30 mM sodium phosphate; 3 wt.% sucrose and having pH of 6.3 to 6.5.

WHAT IS CLAIMED IS:

1. An aqueous etanercept formulation stabilized with sodium chloride, said formulation comprising 25 to 75 mg/ml of etanercept, 75 mM to 150 mM sodium chloride; 1 to 30 mM sodium phosphate, 3 wt % sucrose, wherein the formulation is free of arginine, and where the formulation elicits long term stability.

2. The formulation of claim 1 wherein the formulation elicits long term storage stability as characterized by at least one of:

   SEC analysis at M_3 or T_2 or T_4 of: monomer content greater than 90%; aggregates content of less than 3 wt%; and fragment 3 content less than 5 wt%: and

   HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

3. The formulation of claim 1, wherein the composition has a pH of 6.0 to 6.6; and wherein the composition is characterized by SEC analysis at M_3 or T_2 or T_4 in which: monomer content is greater than 80 wt.%; aggregate(s) content is less than 3 wt.%, and fragment 3 content is less than 8 wt.%.

4. The formulation of claim 1 comprising: 50 mg/ml of etanercept; 75 mM sodium chloride; 10 to 30 mM sodium phosphate; and 3 wt.% sucrose.

5. The formulation of claim 1 comprising: 50 mg/ml of etanercept; 75mM sodium chloride; 10 to 30 mM sodium phosphate; 3 wt.% sucrose and having pH of 6.3 to 6.5.